Biobot Surgical secured $18M in a Series B funding led by Tony Tan for its Mona Lisa surgical robot.

Mar 07, 2024•almost 2 years ago

Amount Raised

$18 Million

Round Type

series b

SingaporeMedicalMedical DeviceBiotechnologyHealth CareManufacturing

Investors

Zig VenturesTony Tan

Description

Biobot Surgical closed a Series B funding round worth $18 million. The round was led by healthcare entrepreneur Tony Tan and saw participation from existing shareholder Zig Ventures. The funds will be used to accelerate the company's global expansion and commercial footprint.

Company Information

Company

Biobot Surgical

Location

Singapore, Southeast Asia, Singapore

About

BIOBOT is a medical technology company dedicated to redefining the standard of care in urology through technological innovation. Its flagship product, the iSR'obot Mona Lisa system, arms urologists with cutting-edge robotic precision and enhanced visualization for percutaneous transperineal procedures.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends